ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00773123
Recruitment Status : Unknown
Verified October 2008 by Yonsei University.
Recruitment status was:  Recruiting
First Posted : October 16, 2008
Last Update Posted : October 16, 2008
Sponsor:
Information provided by:
Yonsei University

Brief Summary:
RT-View utilizes spectral domain technology to assess both RNFL and ganglion cell layer thickness. This study aims to correlate visual field defects in patients with glaucoma to both RNFL and ganglion cell layer thickness.

Condition or disease
Primary Open Angle Glaucoma

Study Type : Observational
Estimated Enrollment : 300 participants
Time Perspective: Prospective
Study Start Date : October 2008
Estimated Primary Completion Date : December 2008
Estimated Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Group/Cohort
1
Primary open angle glaucoma
2
Normal controls



Primary Outcome Measures :
  1. Ganglion cell layer thickness [ Time Frame: 1 month ]

Secondary Outcome Measures :
  1. Visual field defect [ Time Frame: 1 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   10 Years to 90 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
primary open angle glaucoma
Criteria

Exclusion Criteria:

  • Evidence of retinal disease
  • Neovascular glaucoma
  • Secondary glaucoma due to intraocular inflammation
  • Lens induced glaucoma
  • Tumor induced glaucoma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00773123


Contacts
Contact: Chan Yun Kim, MD,PhD 82-2-2228-3570 kangeye@hotmail.com
Contact: Sung Yong Kang, MD 82-2-2228-3570 kangeye@yuhs.ac

Locations
Korea, Republic of
Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University School of Medicine Recruiting
Seoul, Korea, Republic of, 120-752
Contact: Chan Yun Kim, MD,PhD    82-2-2228-3570    kangeye@hotmail.com   
Contact: Sung Yong Kang, MD    82-2-2228-3570    kangeye@yuhs.ac   
Principal Investigator: Chan Yun Kim, MD,PhD.         
Sponsors and Collaborators
Yonsei University

Responsible Party: Kim,Chan Yun, Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University School of Medicine
ClinicalTrials.gov Identifier: NCT00773123     History of Changes
Other Study ID Numbers: 08-0342
First Posted: October 16, 2008    Key Record Dates
Last Update Posted: October 16, 2008
Last Verified: October 2008

Keywords provided by Yonsei University:
RT-View
Spectral domain OCT
Ganglion cell layer
RNFL
Visual field defect

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases